01—Abstract
Summary
Summary of the 8-K filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.
Omega Healthcare Investors, Inc. (NYSE: OHI) reported first quarter 2025 results on May 1, 2025, in a press release furnished as Exhibit 99.1 under Item 2.02.
Net income for the quarter was $112 milliona, or $0.33 per diluted share, compared to $69 million, or $0.27 per share, a year earlier. Nareit FFO was $184 million ($0.62 per share) and Adjusted FFO was $221 million ($0.75 per share), up from $176 million ($0.68 per share) in Q1 2024. Revenues totaled $276.8 million, and the company's indebtedness was $4.5 billion at a weighted-average annual interest rate of 4.6% as of March 31, 2025.
The company raised its 2025 Adjusted FFO guidance to between $2.95b and $3.01 per share, from $2.90 to $2.98 previously. The guidance reflects $423 million of new investments completed through April 2025, including $344 million of U.K. and Jersey acquisitions in April, which the company assumes will be funded with equity issuances. During the quarter, the company issued 7 million common shares for gross proceeds of $264 million, repaid $400 million of senior notes at maturity, and extended its $1.45 billion revolving credit facility to October 30, 2025.
The release also addressed operator credit risk. In March 2025, Genesis Healthcare did not pay its $4.2 millionc contractual rent and missed an interest payment on one of three loans; the company drew $4.3 million on a letter of credit. Genesis paid full contractual rent and interest in April 2025.
The company cited its trailing 12-month EBITDAR coverage for Genesis of above 1.6x and noted $118 milliond of term loan exposure to Genesis. The company also declared a quarterly dividend of $0.67 per share, payable May 15, 2025.
02—Key points
Key Highlights
- Net income of $112 million ($0.33 per diluted share) for Q1 2025, up from $69 million ($0.27 per share) in Q1 2024.
- Adjusted FFO of $221 million ($0.75 per share) for Q1 2025, compared to $176 million ($0.68 per share) a year earlier.
- 2025 Adjusted FFO guidance raised to $2.95–$3.01 per share from $2.90–$2.98 per share.
- Completed $423 million of new investments year-to-date through April 2025, including $344 million of U.K. and Jersey acquisitions in April.
- Genesis Healthcare missed $4.2 million of March rent and one loan interest payment; it paid full contractual rent and interest in April 2025.
- Repaid $400 million of 4.50% senior notes at maturity in January 2025 and extended the $1.45 billion revolving credit facility to October 30, 2025.
- Declared a quarterly dividend of $0.67 per share, payable May 15, 2025 to holders of record on May 5, 2025.
03—Questions
Frequently Asked Questions
How did Omega's core earnings per share perform in the first quarter of 2025?
Nareit FFO was $0.62 per common share, compared to $0.60 in Q1 2024, and Adjusted FFO was $0.75 per common share, compared to $0.68. FAD was $0.71 per share, compared to $0.65 a year earlier.
What happened with Genesis Healthcare, and how much exposure does Omega have?
Genesis did not pay its $4.2 million March rent and missed an interest payment on one of its three loans. Omega drew $4.3 million on a $7.8 million letter of credit and has $3.5 million remaining. Genesis paid full contractual rent and interest in April 2025. Management cited a trailing 12-month EBITDAR coverage above 1.6x and referenced $118 million of term loan exposure.
What is driving the increase in 2025 Adjusted FFO guidance?
The guidance increase reflects Q1 2025 actuals and the impact of $423 million of new investments completed through April 2025. The company assumes the $344 million of April investments will be funded with equity issuances. The guidance also assumes Genesis continues to pay its full contractual obligations and that no additional operators are placed on a cash basis.
How is Omega funding its growth and managing its debt?
In Q1 2025, Omega issued 7 million common shares for gross proceeds of $264 million through its ATM program and dividend reinvestment and stock purchase plan. It repaid $400 million of senior notes and a $50 million term loan in April 2025 using balance sheet cash. As of March 31, 2025, it had $368.0 million of cash and $1.45 billion of undrawn revolver capacity, with total indebtedness of $4.5 billion at a 4.6% weighted-average rate.
What does the filing say about Omega's near-term maturities and liquidity?
The revolving credit facility maturity was extended to October 30, 2025, with one remaining option to extend to April 30, 2026. The guidance assumes repayment of a $238 million secured mortgage loan in November 2025 and balance sheet cash of approximately $600 million at December 31, 2025. The company also holds $247 million of mortgages and real estate-backed investments set to mature in 2025.
04—Continue